Own the gold standard ✨ in financial data & analytics

Name: Eulerpool
Brand: Eulerpool Research Systems
Availability: InStock
Rating: 4,9 (755 reviews)

Subscribe for $2

Overview

Profile

IPCA Laboratories Stock
stock price, forecast, news, chart, split, dividend and analysis IPCA Laboratories ariva, IPCA Laboratories onvista, IPCA Laboratories finanzen.net, IPCA Laboratories aktienfinder, IPCA Laboratories marketscreener, IPCA Laboratories marketwatch, IPCA Laboratories bloomberg, IPCA Laboratories handelsblatt, IPCA Laboratories wiwo, IPCA Laboratories forum

IPCALAB.NS

INE571A01038

Currency:

Price

1,192.75

Today +/-

Today %

+0 %

Ticker
IPCALAB.NS

ISIN
INE571A01038

IPCA Laboratories Revenue, EBIT, Net Income INE571A01038 ·

3 years
5 years
10 years
Max

Revenue

EBIT

Net Income

Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into IPCA Laboratories, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by IPCA Laboratories from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects IPCA Laboratories’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of IPCA Laboratories. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into IPCA Laboratories’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing IPCA Laboratories’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on IPCA Laboratories’s growth potential.

IPCA Laboratories Revenue, EBIT and net profit per share

Date	IPCA Laboratories Revenue	IPCA Laboratories EBIT	IPCA Laboratories Net Income
2027e	118.74 B undefined	19.99 B undefined	14.82 B undefined
2026e	106.43 B undefined	18.2 B undefined	12.2 B undefined
2025e	92.76 B undefined	14.42 B undefined	9.38 B undefined
2024	77.05 B undefined	9.64 B undefined	5.47 B undefined
2023	62.44 B undefined	7 B undefined	4.71 B undefined
2022	58.3 B undefined	10.58 B undefined	8.84 B undefined
2021	54.2 B undefined	13.16 B undefined	11.4 B undefined
2020	46.49 B undefined	7.41 B undefined	6.06 B undefined
2019	37.73 B undefined	5.3 B undefined	4.45 B undefined
2018	32.84 B undefined	2.78 B undefined	2.39 B undefined
2017	32.11 B undefined	2.6 B undefined	1.95 B undefined
2016	29.07 B undefined	1.69 B undefined	931 M undefined
2015	31.42 B undefined	3.53 B undefined	2.54 B undefined
2014	32.82 B undefined	7.09 B undefined	4.79 B undefined
2013	28.13 B undefined	5.39 B undefined	3.24 B undefined
2012	23.59 B undefined	4.43 B undefined	2.77 B undefined
2011	19 B undefined	3.22 B undefined	2.63 B undefined
2010	15.6 B undefined	2.81 B undefined	2.05 B undefined
2009	12.84 B undefined	2.17 B undefined	1.01 B undefined
2008	10.51 B undefined	1.36 B undefined	1.36 B undefined
2007	9.28 B undefined	1.57 B undefined	1.26 B undefined
2006	7.56 B undefined	845 M undefined	615 M undefined
2005	6.79 B undefined	958 M undefined	741 M undefined

	Revenue	EBIT	Net Income
2005	6.79 B INR	958 M INR	741 M INR
2006	7.56 B INR	845 M INR	615 M INR
2007	9.28 B INR	1.57 B INR	1.26 B INR
2008	10.51 B INR	1.36 B INR	1.36 B INR
2009	12.84 B INR	2.17 B INR	1.01 B INR
2010	15.6 B INR	2.81 B INR	2.05 B INR
2011	19 B INR	3.22 B INR	2.63 B INR
2012	23.59 B INR	4.43 B INR	2.77 B INR
2013	28.13 B INR	5.39 B INR	3.24 B INR
2014	32.82 B INR	7.09 B INR	4.79 B INR
2015	31.42 B INR	3.53 B INR	2.54 B INR
2016	29.07 B INR	1.69 B INR	931 M INR
2017	32.11 B INR	2.6 B INR	1.95 B INR
2018	32.84 B INR	2.78 B INR	2.39 B INR
2019	37.73 B INR	5.3 B INR	4.45 B INR
2020	46.49 B INR	7.41 B INR	6.06 B INR
2021	54.2 B INR	13.16 B INR	11.4 B INR
2022	58.3 B INR	10.58 B INR	8.84 B INR
2023	62.44 B INR	7 B INR	4.71 B INR
2024	77.05 B INR	9.64 B INR	5.47 B INR
2025e	92.76 B INR	14.42 B INR	9.38 B INR
2026e	106.43 B INR	18.2 B INR	12.2 B INR
2027e	118.74 B INR	19.99 B INR	14.82 B INR

IPCA Laboratories Stock Ratios

Simple
Expanded

Income Statement
Balance Sheet
Cashflow

REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIVIDEND ()DIV. ()DIVIDEND GROWTH (%)DIV. GROWTH (%)SHARES (M)DOCUMENTS

1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
3.16	3.4	3.58	4.15	4.65	6.06	6.79	7.56	9.28	10.51	12.84	15.6	19	23.59	28.13	32.82	31.42	29.07	32.11	32.84	37.73	46.49	54.2	58.3	62.44	77.05	92.76	106.43	118.74
-	7.53	5.41	15.94	11.99	30.33	11.99	11.30	22.84	13.25	22.12	21.48	21.81	24.19	19.23	16.66	-4.27	-7.49	10.46	2.27	14.91	23.20	16.59	7.56	7.11	23.39	20.39	14.74	11.56
24.39	24.86	24.56	26.67	27.24	28.58	30.15	28.03	32.66	30.05	36.84	39.68	54.44	56.02	55.57	59.99	57.16	55.55	57.29	58.46	60.39	58.27	62.47	59.16	56.26	66.57	-	-	-
0.77	0.85	0.88	1.11	1.27	1.73	2.05	2.12	3.03	3.16	4.73	6.19	10.34	13.22	15.63	19.69	17.96	16.15	18.4	19.2	22.79	27.09	33.86	34.49	35.13	51.29	0	0	0
0.4	0.42	0.38	0.57	0.65	0.89	0.96	0.85	1.57	1.36	2.17	2.81	3.22	4.43	5.39	7.09	3.53	1.69	2.6	2.78	5.3	7.41	13.16	10.58	7	9.64	14.42	18.2	19.99
12.78	12.39	10.58	13.72	13.87	14.65	14.11	11.18	16.86	12.96	16.93	18.01	16.94	18.77	19.17	21.61	11.23	5.81	8.10	8.45	14.04	15.94	24.28	18.15	11.20	12.51	15.54	17.10	16.84
0.21	0.26	0.21	0.32	0.62	0.74	0.74	0.62	1.26	1.36	1.01	2.05	2.63	2.77	3.24	4.79	2.54	0.93	1.95	2.39	4.45	6.06	11.4	8.84	4.71	5.47	9.38	12.2	14.82
-	21.96	-21.46	54.15	97.15	18.78	0.14	-17.00	105.20	7.69	-25.83	103.77	27.95	5.44	16.78	47.87	-46.88	-63.38	108.92	23.08	85.80	36.31	88.03	-22.45	-46.69	16.13	71.41	30.04	21.45
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
250	250	250	250	250	250	250	250	251	251	252	250	251	252	252	252	252	252	252	252	253	253	253	254	253.7	253.76	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Details

Keystats

ⓘ

Revenue and Growth

The IPCA Laboratories Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the IPCA Laboratories is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT ASSETS (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-TERM INVESTMENTS (M)LONG-T. INVEST. (M)LONG-TERM RECEIVABLES (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)OTHER EQUITY (M)UNREALIZED GAINS/LOSSES (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIABILITIES (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)SHORT-TERM DEBTS (M)SHORT-TERM PORTION OF LONG-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM RECEIVABLES (M)SHORT-TERM REC. (M)LONG-TERM LIABILITIES (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIABILITIES (M)OTHER LIAB. (M)LONG-TERM LIABILITIES (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)

Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of IPCA Laboratories provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand IPCA Laboratories's financial health and stability.

Assets

IPCA Laboratories's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that IPCA Laboratories must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of IPCA Laboratories after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into IPCA Laboratories's financial standing, aiding in investment evaluations and risk assessments.

NET INCOME (B)DEPRECIATION AND AMORTIZATION BDEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)Net Cash Flow from Operating Activities (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET DEBT CHANGE (B)Net change in equity (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM FINANCING ACTIVITIES (B)OTHER ITEMS OF FINANCING CASH FLOWS (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)

1999	2000	2001	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
0.25	0.27	0.22	0.8	1.04	0.94	0.75	1.54	1.75	1.18	2.66	3.41	3.64	4.54	6.31	3.61	1.17	2.62	2.91	5.47	7.39	13.81	11.36	7.45
0.07	0.08	0.1	0.13	0.17	0.19	0.25	0.3	0.33	0.4	0.47	0.56	0.67	0.87	1.03	1.8	1.63	1.73	1.78	1.82	2.11	2.09	2.32	2.62
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-0.18	0.14	-0.23	-0.42	-0.32	-0.62	0.06	-0.79	-0.78	-1.13	-1.45	-1.66	-1.68	-1.92	-2.34	-0.82	3.81	-1.55	-1.38	-2.33	-4.16	-4.82	-4.71	-1.75
-0.05	0.16	0.15	0.02	-0.13	0.06	0.16	0.11	-0.24	1.08	0.24	-0.17	0.9	0.39	0.35	0.09	0.48	0.02	0.1	-0.04	0.31	-0.18	-0.37	-0.26
168	161	150	56	41	69	128	212	169	303	291	302	386	364	306	341	318	236	225	167	144	84	62	414
0.01	0.02	0.02	0.18	0.1	0.17	0.09	0.24	0.29	0.22	0.46	0.64	0.8	0.92	1.31	0.75	0.29	0.51	0.58	1.11	1.52	2.46	2.02	2.24
0.1	0.65	0.24	0.53	0.76	0.58	1.21	1.15	1.06	1.52	1.92	2.14	3.54	3.89	5.35	4.68	7.09	2.82	3.41	4.92	5.65	10.9	8.6	8.06
-217	-272	-307	-222	-656	-1,193	-779	-895	-1,438	-898	-1,341	-1,950	-2,605	-2,294	-3,924	-5,583	-2,471	-1,363	-1,367	-1,805	-3,063	-3,616	-4,790	-4,944
-195	-268	-297	-198	-672	-1,150	-745	-902	-1,437	-1,087	-1,174	-1,981	-2,859	-2,599	-3,813	-6,893	-2,183	-1,488	-1,354	-1,563	-5,097	-5,207	-8,551	-7,250
22	4	10	25	-16	43	34	-8	1	-188	167	-31	-254	-305	111	-1,310	288	-125	13	242	-2,034	-1,591	-3,761	-2,305
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0.16	-0.12	0.3	-0.25	0.01	0.8	-0.2	0.19	0.74	0.26	-0.07	0.54	0.13	-0	-0.39	3.21	-4.14	-1.35	-0.93	-1.75	-0.06	-2.32	5.34	6.5
0	0	0	0	0	0	0	0	18	-46	0	22	8	3	0	0	0	0	0	46	119	358	0	0
0.09	-0.36	0.06	-0.33	-0.07	0.56	-0.46	-0.21	0.37	-0.42	-0.74	-0.18	-0.72	-0.83	-1.36	2.51	-4.62	-1.59	-1.3	-1.83	-1.31	-3.06	4.27	5.07
0	-161	-158	-15	120	-88	-110	-211	-169	-303	-291	-302	-386	-364	-306	-341	-318	-236	-225	22	-144	-84	-62	-414
-69	-80	-85	-67	-196	-155	-157	-185	-219	-336	-379	-439	-467	-468	-661	-369	-153	-2	-153	-154	-1,217	-1,015	-1,015	-1,014
-0.01	0.02	0.01	-0	0.02	-0.01	0.01	0.05	-0.01	0.01	0	-0.02	-0.04	0.46	0.18	0.29	0.29	-0.26	0.75	1.53	-0.76	2.64	4.32	5.88
-118	373	-66	304	107	-615	433	259	-378	626	574	192	933	1,594	1,426	-901	4,616	1,456	2,044	3,118	2,583	7,285	3,812	3,113.4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

IPCA Laboratories stock margins INE571A01038 ·

The IPCA Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IPCA Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IPCA Laboratories.

3 years
5 years
10 years
Max

Gross margin

EBIT margin

Profit margin

Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the IPCA Laboratories's sales revenue. A higher gross margin percentage indicates that the IPCA Laboratories retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the IPCA Laboratories's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the IPCA Laboratories's total revenue generated. When comparing the revenue margin year over year, investors can gauge the IPCA Laboratories's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the IPCA Laboratories. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the IPCA Laboratories's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

IPCA Laboratories Margin History

IPCA Laboratories Gross margin	IPCA Laboratories Profit margin	IPCA Laboratories EBIT margin	IPCA Laboratories Profit margin
2027e	66.57 %	16.84 %	12.48 %
2026e	66.57 %	17.1 %	11.46 %
2025e	66.57 %	15.54 %	10.11 %
2024	66.57 %	12.51 %	7.1 %
2023	56.26 %	11.2 %	7.55 %
2022	59.16 %	18.15 %	15.17 %
2021	62.47 %	24.28 %	21.03 %
2020	58.27 %	15.94 %	13.04 %
2019	60.39 %	14.04 %	11.79 %
2018	58.46 %	8.45 %	7.29 %
2017	57.29 %	8.1 %	6.06 %
2016	55.55 %	5.81 %	3.2 %
2015	57.16 %	11.23 %	8.09 %
2014	59.99 %	21.61 %	14.58 %
2013	55.57 %	19.17 %	11.5 %
2012	56.02 %	18.77 %	11.74 %
2011	54.44 %	16.94 %	13.83 %
2010	39.68 %	18.01 %	13.17 %
2009	36.84 %	16.93 %	7.85 %
2008	30.05 %	12.96 %	12.93 %
2007	32.66 %	16.86 %	13.59 %
2006	28.03 %	11.18 %	8.14 %
2005	30.15 %	14.11 %	10.91 %

	Gross margin	EBIT margin	Profit margin
2005	30.15 %	14.11 %	10.91 %
2006	28.03 %	11.18 %	8.14 %
2007	32.66 %	16.86 %	13.59 %
2008	30.05 %	12.96 %	12.93 %
2009	36.84 %	16.93 %	7.85 %
2010	39.68 %	18.01 %	13.17 %
2011	54.44 %	16.94 %	13.83 %
2012	56.02 %	18.77 %	11.74 %
2013	55.57 %	19.17 %	11.5 %
2014	59.99 %	21.61 %	14.58 %
2015	57.16 %	11.23 %	8.09 %
2016	55.55 %	5.81 %	3.2 %
2017	57.29 %	8.1 %	6.06 %
2018	58.46 %	8.45 %	7.29 %
2019	60.39 %	14.04 %	11.79 %
2020	58.27 %	15.94 %	13.04 %
2021	62.47 %	24.28 %	21.03 %
2022	59.16 %	18.15 %	15.17 %
2023	56.26 %	11.2 %	7.55 %
2024	66.57 %	12.51 %	7.1 %
2025e	66.57 %	15.54 %	10.11 %
2026e	66.57 %	17.1 %	11.46 %
2027e	66.57 %	16.84 %	12.48 %

IPCA Laboratories Stock Sales Revenue, EBIT, Earnings per Share INE571A01038 ·

The IPCA Laboratories earnings per share therefore indicates how much revenue IPCA Laboratories has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

3 years
5 years
10 years
Max

Sales per Share

EBIT per share

Earnings per Share

Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IPCA Laboratories earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IPCA Laboratories's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IPCA Laboratories’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IPCA Laboratories's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

IPCA Laboratories Revenue, EBIT and net profit per share

Date	IPCA Laboratories Sales per Share	IPCA Laboratories EBIT per share	IPCA Laboratories Earnings per Share
2027e	468.01 undefined	0 undefined	58.4 undefined
2026e	419.51 undefined	0 undefined	48.08 undefined
2025e	365.63 undefined	0 undefined	36.98 undefined
2024	303.64 undefined	37.99 undefined	21.57 undefined
2023	246.13 undefined	27.57 undefined	18.58 undefined
2022	229.52 undefined	41.67 undefined	34.81 undefined
2021	214.23 undefined	52.01 undefined	45.06 undefined
2020	183.74 undefined	29.28 undefined	23.96 undefined
2019	149.14 undefined	20.94 undefined	17.58 undefined
2018	130.3 undefined	11.01 undefined	9.5 undefined
2017	127.4 undefined	10.32 undefined	7.72 undefined
2016	115.34 undefined	6.7 undefined	3.69 undefined
2015	124.67 undefined	14 undefined	10.09 undefined
2014	130.23 undefined	28.14 undefined	18.99 undefined
2013	111.63 undefined	21.4 undefined	12.84 undefined
2012	93.63 undefined	17.57 undefined	11 undefined
2011	75.69 undefined	12.82 undefined	10.47 undefined
2010	62.38 undefined	11.24 undefined	8.22 undefined
2009	50.94 undefined	8.62 undefined	4 undefined
2008	41.88 undefined	5.43 undefined	5.41 undefined
2007	36.98 undefined	6.24 undefined	5.03 undefined
2006	30.23 undefined	3.38 undefined	2.46 undefined
2005	27.16 undefined	3.83 undefined	2.96 undefined

	Sales per Share	EBIT per share	Earnings per Share
2005	27.16 INR	3.83 INR	2.96 INR
2006	30.23 INR	3.38 INR	2.46 INR
2007	36.98 INR	6.24 INR	5.03 INR
2008	41.88 INR	5.43 INR	5.41 INR
2009	50.94 INR	8.62 INR	4 INR
2010	62.38 INR	11.24 INR	8.22 INR
2011	75.69 INR	12.82 INR	10.47 INR
2012	93.63 INR	17.57 INR	11 INR
2013	111.63 INR	21.4 INR	12.84 INR
2014	130.23 INR	28.14 INR	18.99 INR
2015	124.67 INR	14 INR	10.09 INR
2016	115.34 INR	6.7 INR	3.69 INR
2017	127.4 INR	10.32 INR	7.72 INR
2018	130.3 INR	11.01 INR	9.5 INR
2019	149.14 INR	20.94 INR	17.58 INR
2020	183.74 INR	29.28 INR	23.96 INR
2021	214.23 INR	52.01 INR	45.06 INR
2022	229.52 INR	41.67 INR	34.81 INR
2023	246.13 INR	27.57 INR	18.58 INR
2024	303.64 INR	37.99 INR	21.57 INR
2025e	365.63 INR	0 INR	36.98 INR
2026e	419.51 INR	0 INR	48.08 INR
2027e	468.01 INR	0 INR	58.4 INR

IPCA Laboratories business model

IPCA Laboratories is one of the most popular companies on Eulerpool.com.

IPCA Laboratories valuation based on historical P/E ratio, EBIT, and P/S ratio.

IPCA Laboratories shares outstanding INE571A01038 ·

The number of shares was IPCA Laboratories in 2023 — This indicates how many shares 253.704 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

3 years
5 years
10 years
Max

Number of stocks

Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

	Number of stocks
2005	250 M Aktien
2006	250 M Aktien
2007	251 M Aktien
2008	251 M Aktien
2009	252 M Aktien
2010	250 M Aktien
2011	251 M Aktien
2012	252 M Aktien
2013	252 M Aktien
2014	252 M Aktien
2015	252 M Aktien
2016	252 M Aktien
2017	252 M Aktien
2018	252 M Aktien
2019	253 M Aktien
2020	253 M Aktien
2021	253 M Aktien
2022	254 M Aktien
2023	253.7 M Aktien
2024	253.76 M Aktien
2025e	253.76 M Aktien
2026e	253.76 M Aktien
2027e	253.76 M Aktien

IPCA Laboratories Stock splits

In IPCA Laboratories's history, there have been no stock splits.

IPCA Laboratories Stock Dividend INE571A01038 ·

In 2023, IPCA Laboratories paid a dividend amounting to 2 INR. Dividend means that IPCA Laboratories distributes a portion of its profits to its owners.

3 years
5 years
10 years
Max

Dividend

Dividend (Estimate)

Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for IPCA Laboratories provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify IPCA Laboratories’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating IPCA Laboratories's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

IPCA Laboratories Dividend History

Date	IPCA Laboratories Dividend
2023	2 undefined
2022	4 undefined
2021	4 undefined
2020	6.5 undefined
2019	1.5 undefined
2018	0.5 undefined
2017	0.5 undefined
2015	0.5 undefined
2014	1.25 undefined
2013	2.25 undefined
2012	2.1 undefined
2011	1.6 undefined
2010	1.4 undefined
2009	1.2 undefined
2008	0.85 undefined
2007	0.75 undefined
2006	0.65 undefined
2005	0.55 undefined

	Dividend	Dividend (Estimate)
2005	0.55 INR	0 INR
2006	0.65 INR	0 INR
2007	0.75 INR	0 INR
2008	0.85 INR	0 INR
2009	1.2 INR	0 INR
2010	1.4 INR	0 INR
2011	1.6 INR	0 INR
2012	2.1 INR	0 INR
2013	2.25 INR	0 INR
2014	1.25 INR	0 INR
2015	0.5 INR	0 INR
2016	0 INR	0 INR
2017	0.5 INR	0 INR
2018	0.5 INR	0 INR
2019	1.5 INR	0 INR
2020	6.5 INR	0 INR
2021	4 INR	0 INR
2022	4 INR	0 INR
2023	2 INR	0 INR
2024	0 INR	0 INR
2025e	0 INR	0 INR
2026e	0 INR	0 INR
2027e	0 INR	0 INR

IPCA Laboratories Stock Payout Ratio INE571A01038 ·

In 2023, IPCA Laboratories had a payout ratio of 15.83%. The payout ratio indicates the percentage of the company's profits that IPCA Laboratories distributes as dividends.

3 years
5 years
10 years
Max

Payout ratio

Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for IPCA Laboratories represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for IPCA Laboratories could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate IPCA Laboratories's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

IPCA Laboratories Payout Ratio History

Date	IPCA Laboratories Payout ratio
2027e	12.96 %
2026e	13.67 %
2025e	13.13 %
2024	12.07 %
2023	15.83 %
2022	11.49 %
2021	8.88 %
2020	27.11 %
2019	8.53 %
2018	5.27 %
2017	6.49 %
2016	15.83 %
2015	4.97 %
2014	6.59 %
2013	17.52 %
2012	19.11 %
2011	15.28 %
2010	17.07 %
2009	30 %
2008	15.71 %
2007	14.94 %
2006	26.42 %
2005	18.58 %

	Payout ratio
2005	18.58 %
2006	26.42 %
2007	14.94 %
2008	15.71 %
2009	30 %
2010	17.07 %
2011	15.28 %
2012	19.11 %
2013	17.52 %
2014	6.59 %
2015	4.97 %
2016	15.83 %
2017	6.49 %
2018	5.27 %
2019	8.53 %
2020	27.11 %
2021	8.88 %
2022	11.49 %
2023	15.83 %
2024	12.07 %
2025e	13.13 %
2026e	13.67 %
2027e	12.96 %

Unfortunately, there are currently no price targets and forecasts available for IPCA Laboratories.

IPCA Laboratories Earnings Surprises

Date	EPS Estimate	EPS Actual	Quarterly report
3/31/2024	5.2	7.74 (48.79 %)	2024 Q4
12/31/2023	5.71	7.09 (24.12 %)	2024 Q3
9/30/2023	7.24	5.72 (-21.02 %)	2024 Q2
6/30/2023	4.9	6.42 (31.13 %)	2024 Q1
3/31/2023	6.85	3.02 (-55.92 %)	2023 Q4
12/31/2022	9.76	4.25 (-56.44 %)	2023 Q3
9/30/2022	9.85	5.67 (-42.43 %)	2023 Q2
6/30/2022	9.26	5.64 (-39.1 %)	2023 Q1
3/31/2022	10.69	5.13 (-52.02 %)	2022 Q4
12/31/2021	18.56	7.76 (-58.18 %)	2022 Q3
9/30/2021	11.8	9.87 (-16.36 %)	2022 Q2
6/30/2021	12.44	12.09 (-2.84 %)	2022 Q1
3/31/2021	9.17	6.36 (-30.68 %)	2021 Q4
12/31/2020	10.2	10.55 (3.38 %)	2021 Q3
9/30/2020	10.77	10.54 (-2.1 %)	2021 Q2
6/30/2020	7.67	17.62 (129.64 %)	2021 Q1
3/31/2020	5.7	3.29 (-42.4 %)	2020 Q4
12/31/2019	6.4	7.77 (21.39 %)	2020 Q3
9/30/2019	5.67	7.66 (34.99 %)	2020 Q2
6/30/2019	5.05	5.12 (1.3 %)	2020 Q1

Eulerpool ESG Scorecard© for the IPCA Laboratories stock

Eulerpool World ESG Rating (EESG©)

52/ 100

🌱 Environment

👫 Social

🏛️ Governance

Environment

Scope 1 - Direct Emissions	—
Scope 2 - Indirect emissions from purchased energy	—
Scope 3 - Indirect emissions within the value chain	—
Total CO₂ emissions	—
CO₂ reduction strategy	✅
Coal energy	❌
Nuclear power	❌
Animal experiments	✅
Fur & Leather	—
Pesticides	—
Palm Oil	—
Tobacco	❌
Genetically modified organisms	❌
Climate concept	—
Sustainable forestry	—
Recycling regulations	❌
Environmentally friendly packaging	❌
Hazardous substances	❌
Fuel consumption and efficiency	❌
Water consumption and efficiency	✅

Social

Percentage of female employees	6.295
Percentage of women in management	—
Percentage of Asian employees	—
Share of Asian management	—
Percentage of Hispanic/Latino employees	—
Hispano/Latino Management share	—
Percentage of Black employees	—
Black Management Share	—
Percentage of white employees	—
White Management Share	—
Adult content	❌
Alcohol	❌
Weapons	—
Firearms	❌
Gambling	❌
Military contracts	❌
Human rights concept	✅
Privacy concept	—
Occupational health and safety	✅
Catholic	✅

Governance (Corporate Governance)

Environmental reporting	✅
Stakeholder Engagement	❌
Call Back Policies	❌
Antitrust law	❌

Kontaktformular an uns. The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

IPCA Laboratories Stock Shareholders

%	Name	Stocks	Change	Date
7.02 %	HDFC Asset Management Co., Ltd.	17,803,069	24	3/31/2024
6.90 %	DSP Investment Managers Pvt. Ltd.	17,497,289	431,726	12/31/2023
6.61 %	Kaygee Laboratories Pvt. Ltd.	16,770,000	0	12/31/2023
5.50 %	Chandurkar Investments Pvt. Ltd.	13,956,010	0	12/31/2023
5.00 %	Kotak Mahindra Asset Management Company Limited	12,688,939	185,336	12/31/2023
4.01 %	Paschim Chemicals Pvt. Ltd.	10,173,000	35,000	3/11/2024
3.27 %	Chandurkar (Usha M)	8,302,000	0	12/31/2023
21.47 %	Kaygee Investments Pvt. Ltd.	54,478,390	0	12/31/2023
2.52 %	ICICI Prudential Asset Management Co. Ltd.	6,391,303	-62,730	3/31/2024
2.29 %	Godha (Premchand)	5,814,680	0	12/31/2023
1.97 %	HDFC Life Insurance Company Limited	4,993,600	169,231	12/31/2023
1.73 %	SBI Life Insurance Co., Ltd.	4,398,070	168,000	12/31/2023
1.70 %	Nippon Life India Asset Management Limited	4,302,177	51,079	3/31/2024
1.64 %	The Vanguard Group, Inc.	4,163,968	-57,677	3/31/2024
1.46 %	PPFAS Asset Management Private Limited	3,716,750	0	12/31/2023
1.37 %	UTI Asset Management Co. Ltd.	3,488,099	-14,692	3/31/2024
1.36 %	Kotak Mahindra Asset Management (Singapore) Pte. Ltd.	3,450,394	178,848	2/29/2024
1.03 %	Abu Dhabi Investment Authority	2,611,923	2,611,923	12/31/2023
0.95 %	Godha (Usha)	2,418,740	0	12/31/2023
0.86 %	MFS Investment Management	2,191,545	0	2/29/2024
0.84 %	Kotak Mahindra (UK) Ltd	2,140,927	0	8/31/2022
0.79 %	Chandurkar (Sameer)	2,000,000	0	12/31/2023
0.77 %	HSBC Global Asset Management (India) Private Limited	1,946,300	0	3/31/2024
0.77 %	Axis Asset Management Company Limited	1,944,189	-110	3/31/2024
0.76 %	Dimensional Fund Advisors, L.P.	1,929,491	-6,433	2/29/2024
0.74 %	BlackRock Institutional Trust Company, N.A.	1,886,671	10,530	3/31/2024
0.67 %	Godha (Pranay)	1,700,990	0	12/31/2023
0.62 %	Godha (Prashant)	1,568,644	0	12/31/2023
0.59 %	Franklin Templeton Asset Management (India) Pvt. Ltd.	1,491,580	0	3/31/2024
0.50 %	Quant Money Managers Ltd	1,268,332	0	3/31/2024
0.46 %	Norges Bank Investment Management (NBIM)	1,172,918	-148	12/31/2023
0.30 %	Investor Education Protection Fund	762,612	-22,012	12/31/2023
0.26 %	Motilal Oswal Asset Management Company Ltd.	654,805	12,583	3/31/2024
0.20 %	Invesco Asset Management (India) Private Limited	503,426	-14,950	3/31/2024
0.18 %	Tata Asset Management Ltd.	466,499	12,037	3/31/2024
0.17 %	BlackRock Advisors (UK) Limited	436,523	3,040	3/31/2024
0.12 %	Bandhan Asset Management Company Limited	298,004	57,577	3/31/2024
0.11 %	HSBC Global Asset Management (Hong Kong) Limited	270,994	-2,508	11/30/2022
0.10 %	Edelweiss Asset Management Ltd.	242,144	-104,830	3/31/2024
0.09 %	Jain (Kalpana)	230,000	0	12/31/2023
0.09 %	Mellon Investments Corporation	219,981	7,824	3/31/2024
0.09 %	Dimensional Fund Advisors, Ltd.	219,525	0	2/29/2024
0.08 %	Mahindra Manulife Investment Management Private Limited	200,000	0	3/31/2024
0.08 %	State Street Global Advisors (UK) Ltd.	191,938	1	3/31/2024
0.07 %	Robeco Hong Kong Limited	187,404	40,707	2/29/2024
0.07 %	State Street Global Advisors (US)	185,726	-319	2/29/2024
0.07 %	Charles Schwab Investment Management, Inc.	179,189	0	3/31/2024
0.07 %	Mirae Asset Global Investments Co., Ltd.	178,862	0	9/30/2023
0.07 %	JM Financial Asset Management Pvt. Ltd.	172,500	0	3/31/2024
0.06 %	Baroda BNP Paribas Asset Management India Pvt. Ltd.	150,000	0	3/31/2024
0.06 %	Mirae Asset Global Investments (Hong Kong) Limited	142,977	0	9/30/2023
0.05 %	Franklin Templeton Portfolio Advisors, Inc	136,259	11,202	3/31/2024
0.05 %	PGGM Vermogensbeheer B.V.	129,758	63,197	7/31/2023
0.05 %	Nuveen LLC	114,682	0	3/31/2024
0.04 %	Bank J. Safra Sarasin AG (Asset Management)	106,978	-8,725	8/31/2022
0.04 %	BlackRock Investment Management (UK) Ltd.	92,510	0	11/30/2023
0.03 %	Principal Asset Management Pvt. Ltd.	79,880	0	3/31/2024
0.03 %	White Oak Capital Management Consultants Llp	78,079	0	3/31/2024
0.03 %	American Century Investment Management, Inc.	75,155	0	3/31/2024
0.02 %	Geode Capital Management, L.L.C.	57,315	0	2/29/2024
0.02 %	Jain (Ajit Kumar)	42,000	-20,000	11/17/2023
0.01 %	Legal & General Investment Management Ltd.	37,775	0	2/29/2024
0.01 %	State Street Global Advisors Ireland Limited	33,618	-796	3/31/2024
0.01 %	LIC Mutual Fund Asset Management Company Ltd.	32,391	833	3/31/2024
0.01 %	Paranthapa Investments & Traders Pvt. Ltd.	31,000	0	12/31/2023
0.01 %	HSBC Global Asset Management (UK) Limited	30,645	0	2/29/2024
0.01 %	Invesco Capital Management LLC	24,996	-966	3/31/2024
0.01 %	IDBI Asset Management Limited	21,440	0	3/31/2024
0.01 %	Aditya Birla Sun Life AMC Limited	20,997	1,558	3/31/2024
0.01 %	Storebrand Kapitalforvaltning AS	20,589	0	2/29/2024
0.01 %	ITI Asset Management Limited	19,066	0	3/31/2024
0.01 %	SBI Funds Management Pvt. Ltd.	17,920	788	3/31/2024
0.01 %	Vanguard Global Advisers LLC	15,290	58	2/29/2024
0.01 %	Mexin Medicaments Pvt. Ltd.	14,058	0	12/31/2023
0.01 %	Babu (E. J.)	14,000	14,000	9/15/2022
0.01 %	Vanguard Investments Australia Ltd.	13,724	12	2/29/2024
0.00 %	DFA Australia Ltd.	11,305	8,563	12/31/2023
0.00 %	Parametric Portfolio Associates LLC	6,080	0	1/31/2024
0.00 %	Navi AMC Limited	5,981	236	3/31/2024
0.00 %	Taurus Asset Management Co. Ltd.	5,610	5,610	3/31/2024
0.00 %	Godha (Bhawna)	5,000	0	12/31/2023
0.00 %	Mackenzie Financial Corporation	4,584	-563	3/31/2024
0.00 %	Prudential Capital Group	4,300	0	11/30/2022
0.00 %	Godha (Neetu)	4,000	0	12/31/2023
0.00 %	Northern Trust Investments, Inc.	3,950	0	3/31/2024
0.00 %	Avantis Investors	3,384	0	3/31/2024
0.00 %	Scottish Equity Partners LLP	3,254	0	2/29/2024
0.00 %	Dimensional Fund Advisors Canada ULC	1,548	0	11/30/2023
0.00 %	Makers Laboratories Ltd	960	0	12/31/2023
0.00 %	Groww Asset Management Ltd	905	56	3/31/2024
0.00 %	Franklin Advisory Services, LLC	744	0	3/31/2024
0.00 %	WhiteOak Capital Asset Management Limited	671	0	3/31/2024
0.00 %	Franklin Advisers, Inc.	346	0	3/31/2024
0.00 %	Irish Life Investment Managers Ltd.	114	-24	3/31/2024
0 %	Union Asset Management Company Private Limited	0	-7,150	7/31/2023
0 %	NJ Asset Management Private Limited	0	-303,510	10/31/2022
0 %	PGIM India Asset Management Private Limited	0	-650	6/30/2023
0 %	SEI Investments Management Corporation	0	-101,568	2/28/2023
0 %	CPP Investment Board	0	-69,000	3/31/2023
0 %	Wellington Management Japan Pte Ltd	0	-389,814	6/30/2023

...

IPCA Laboratories Executives and Management Board

Shri. Premchand Godha76

IPCA Laboratories Executive Chairman of the Board (since 1975)

Compensation 112.65 M

Mr. Ajit Jain67

IPCA Laboratories Chief Financial Officer, Managing Director, Executive Director (since 1994)

Compensation 77.54 M

Mr. Pranay Godha50

IPCA Laboratories Chief Executive Officer, Managing Director, Executive Director (since 2006)

Compensation 50.98 M

Mr. Prashant Godha49

IPCA Laboratories Executive Director (since 2011)

Compensation 46 M

Mr. Harish Kamath62

IPCA Laboratories Corporate Counsel, Company Secretary, Compliance Officer (since 2021)

Compensation 15.48 M

Mr. Kamal Seth76

IPCA Laboratories Non-Executive Independent Director

Compensation 1.4 M

Mr. Anand Kusre

IPCA Laboratories Non-Executive Independent Director

Compensation 1.05 M

Dr. Mrs. Manisha Premnath

IPCA Laboratories Non-Executive Independent Director

Compensation 950,000

Dr. Narendra Mairpady69

IPCA Laboratories Non-Executive Independent Director

Compensation 600,000

Mr. Pabitra Bhattacharya52

IPCA Laboratories President - Operations (API)

Mr. Sunil Ghai59

IPCA Laboratories President - Marketing

Dr. Sanjay Kapadia60

IPCA Laboratories President - Corporate Quality Assurance

Dr. Ashok Kumar68

IPCA Laboratories President - Research and Development (Chemicals)

Mr. Shailesh Laul

IPCA Laboratories President - Operations (Formulations)

Mr. Hitesh Maheshwari49

IPCA Laboratories President - Research and Development (Formulations)

Mr. Shashil Mendonsa49

IPCA Laboratories President - International Marketing

Dr. Anil Pareek63

IPCA Laboratories President - Medical Affairs and Clinical Research

Ms. Kavita Sehwani51

IPCA Laboratories President - Generics

Dr. Swati Patankar56

IPCA Laboratories Additional Non-Executive Independent Director

IPCA Laboratories stock: Frequently Asked Questions

What is the P/E ratio of IPCA Laboratories 2024?

The IPCA Laboratories P/E ratio is 55.3.

What is the P/S ratio of IPCA Laboratories 2024?

The IPCA Laboratories P/S ratio is 3.93.

What is the AlleAktien quality score of IPCA Laboratories?

The AlleAktien quality score for IPCA Laboratories is 5/10.

What is the revenue of IPCA Laboratories 2024?

The IPCA Laboratories revenue is 77.05 B INR.

How high is the profit of IPCA Laboratories 2024?

The IPCA Laboratories profit is 5.47 B INR.

What is the business model of IPCA Laboratories

No history available for IPCA Laboratories.

What is the IPCA Laboratories dividend?

IPCA Laboratories pays a dividend of 4 INR distributed over payouts per year.

How often does IPCA Laboratories pay dividends?

The dividend cannot currently be calculated for IPCA Laboratories or the company does not pay out a dividend.

What is the IPCA Laboratories ISIN?

The ISIN of IPCA Laboratories is INE571A01038.

What is the IPCA Laboratories ticker?

The ticker of IPCA Laboratories is IPCALAB.NS.

How much dividend does IPCA Laboratories pay?

Over the past 12 months, IPCA Laboratories paid a dividend of 2 INR . This corresponds to a dividend yield of about 0.17 %. For the coming 12 months, IPCA Laboratories is expected to pay a dividend of 2 INR.

What is the dividend yield of IPCA Laboratories?

The current dividend yield of IPCA Laboratories is 0.17 %.

When does IPCA Laboratories pay dividends?

IPCA Laboratories pays a quarterly dividend. This is distributed in the months of December, December, December, December.

How secure is the dividend of IPCA Laboratories?

IPCA Laboratories paid dividends every year for the past 3 years.

What is the dividend of IPCA Laboratories?

For the upcoming 12 months, dividends amounting to 2 INR are expected. This corresponds to a dividend yield of 0.17 %.

In which sector is IPCA Laboratories located?

IPCA Laboratories is assigned to the 'Health' sector.

Wann musste ich die Aktien von IPCA Laboratories kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IPCA Laboratories from 12/5/2023 amounting to 2 INR, you needed to have the stock in your portfolio before the ex-date on 11/22/2023.

When did IPCA Laboratories pay the last dividend?

The last dividend was paid out on 12/5/2023.

What was the dividend of IPCA Laboratories in the year 2023?

In the year 2023, IPCA Laboratories distributed 4 INR as dividends.

In which currency does IPCA Laboratories pay out the dividend?

The dividends of IPCA Laboratories are distributed in INR.

IPCA Laboratories stock price, news, forecast, analysis

Sector

Health

Industry

Pharmaceuticals

Number of shares

253,704,000

Employee

16,167

Revenue growth Ø5 years

10.63 %

EBIT growth Ø5 years

5.4 %

Net Income growth Ø5 years

-2.02 %

Website

IPCA Laboratories

Country

India 🇮🇳

Currency

INR

Initial public offering

Feb 23, 1994

GOSIN

Global Open Securities Identification Number

Cusip

Y4175R161

Market capitalization

288.4 B

AAQS

Details

5 / 10

PEG

3.36

P/E

55.3

Forward P/E

32.26

P/S

3.93

Forward P/S

3.26

ROE (Return on Equity)

9.37 %

ROA (Return on Assets)

6.35 %

ROCE (Return on Capital Employed)

14.13 %

ROIC

6.09 %

Scalable Capital savings plan

Nein

Trade Republic savings plan

Nein

comdirect savings plan

Consorsbank savings plan

Nein

ING savings plan

Nein

IPCA Laboratories Peer Group

IPCA Laboratories Eulerpool News

IPCA Laboratories News

All IPCA Laboratories News

IPCA Laboratories Ticker

Stock Exchange	IPCA Laboratories Ticker
	IPCALAB.BO
NEW YORK	IPCALAB.NS

IPCA Laboratories FIGI

IPCA Laboratories Ticker	IPCA Laboratories FIGI
IPCA:IN	BBG000D4LPY0
IPCA:IB	BBG000D4LQN0
IPCA:IS	BBG000D4LR21
IPCA:IG	BBG003NVYQ40

Other fundamentals and analyses of IPCA Laboratories in the deep dive.

Our stock analysis for IPCA Laboratories Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IPCA Laboratories Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Own the gold standard ✨ in financial data & analytics

Price

Price

TickerIPCALAB.NS

ISININE571A01038

IPCA Laboratories Revenue, EBIT, Net Income INE571A01038 ·

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

IPCA Laboratories Revenue, EBIT and net profit per share

IPCA Laboratories Stock Ratios

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

IPCA Laboratories stock margins INE571A01038 ·

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

IPCA Laboratories Margin History

IPCA Laboratories Stock Sales Revenue, EBIT, Earnings per Share INE571A01038 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

IPCA Laboratories Revenue, EBIT and net profit per share

IPCA Laboratories business model

IPCA Laboratories valuation based on historical P/E ratio, EBIT, and P/S ratio.

IPCA Laboratories shares outstanding INE571A01038 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

IPCA Laboratories Stock splits

IPCA Laboratories Stock Dividend INE571A01038 ·

Dividend

Dividend Overview

Interpretation and Use

Investment Strategy

IPCA Laboratories Dividend History

IPCA Laboratories Stock Payout Ratio INE571A01038 ·

Payout ratio

What is Yearly Payout Ratio?

How to Interpret the Data

Using the Data for Investments

IPCA Laboratories Payout Ratio History

IPCA Laboratories Earnings Estimates

IPCA Laboratories Earnings Surprises

Eulerpool ESG Scorecard© for the IPCA Laboratories stock

Eulerpool World ESG Rating (EESG©)

52/ 100

🌱 Environment

👫 Social

🏛️ Governance

Environment

Social

Governance (Corporate Governance)

IPCA Laboratories Stock Shareholders

IPCA Laboratories Executives and Management Board

IPCA Laboratories stock: Frequently Asked Questions

What is the P/E ratio of IPCA Laboratories 2024?

What is the P/S ratio of IPCA Laboratories 2024?

Ticker
IPCALAB.NS

ISIN
INE571A01038